<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483626</url>
  </required_header>
  <id_info>
    <org_study_id>Thorax-001-2003</org_study_id>
    <nct_id>NCT00483626</nct_id>
  </id_info>
  <brief_title>Hemodynamic Response After Six Months of Sildenafil</brief_title>
  <official_title>Hemodynamic Evaluation of Patients With Pulmonary Arterial Hypertension. Response to Sildenafil Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chile</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the clinical, functional and hemodynamic response
      after six months of sildenafil 50 mg TID in patients with pulmonary arterial hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary arterial hypertension is a chronic devastating disease. There are few approval oral
      treatments. Sildenafil, a phosphodiesterase 5 inhibitors, has been recently approved for
      patients on functional class II and III showing hemodynamic benefits after 12 weeks of
      treatment. Long term hemodynamic evaluation after sildenafil treatment has not been
      evaluating in pulmonary arterial patients on functional class II to IV.

      The protocol has been designed to evaluate patients on functional class II to IV from
      baseline conditions and after 6 months of sildenafil treatment (50 mg po TID). Clinical
      (functional class), functional (walked distance-6 minute walking test) and Hemodynamic
      evaluation is planned to be performed at baseline and after 6 months of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2003</start_date>
  <completion_date type="Anticipated">June 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial pulmonary resistance index</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean pulmonary arterial pressure, Cardiac index, pulmonary saturation, walked distance, functional class.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral sildenafil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 15 years old with Pulmonary arterial hypertension according with
             WHO hemodynamic definition,

          -  Who signed informed consent,

          -  Able to swallow tablets and follow instructions.

        Exclusion Criteria:

          -  Patients with pulmonary hypertension with other categories than pulmonary arterial
             hypertension (associated to COPD, lund diseases, sleep apnea, thromboembolic disease,
             hight altitude), patients asymptomatic, patients who were responders to adenosine
             during hemodynamic test, patients treated with specific treatments for pulmonary
             arterial hypertension before started the study such as sildenafil, prostanoids,
             endothelin receptors blockers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica M Zagolin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Thorax</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monica M Zagolin, MD</last_name>
    <phone>056-2-3403505</phone>
    <phone_ext>504</phone_ext>
    <email>monizagolin@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Polentzi Uriarte, MD</last_name>
    <phone>056-2-3403505</phone>
    <phone_ext>504</phone_ext>
    <email>puriarte@alemana.cl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Instiute of Thorax</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitanta</state>
        <zip>7500691</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Polentzi Uriarte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica M Zagolin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduardo Wainsteiin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudio Parra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Gali√® N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 Nov 17;353(20):2148-57. Erratum in: N Engl J Med. 2006 Jun 1;354(22):2400-1.</citation>
    <PMID>16291984</PMID>
  </reference>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2007</study_first_submitted>
  <study_first_submitted_qc>June 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2007</study_first_posted>
  <last_update_submitted>June 6, 2007</last_update_submitted>
  <last_update_submitted_qc>June 6, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2007</last_update_posted>
  <keyword>hemodynamic</keyword>
  <keyword>pulmonary hypertension</keyword>
  <keyword>sildenafil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

